Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1Classical hematology 1

Conditions

Primary Myelofibrosis 3Myelodysplastic Syndromes 3Anemia 3beta-Thalassemia 2Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × luspatercept × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT01688011 2025-07-03

Connect® Myeloid Disease Registry

Celgene

Terminated
2,013 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed
229 enrolled 36 charts 1 FDA
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡